Navigation Links
Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
Date:2/22/2010

/p>

LIDODERM®:  For the quarter ended Dec. 31, 2009, net sales of LIDODERM were $204 million, compared with $205 million reported in the same period a year ago.  For the year end, net sales of LIDODERM were relatively flat at $764 million, compared with $765 million in the same period a year ago.  The company expects low single-digit growth for LIDODERM in 2010.  

On Feb. 19, 2010, Endo and the holders of the LIDODERM new drug application and relevant patent, Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc., filed a lawsuit against Watson Laboratories, Inc. in the United States District Court for the District of Delaware in connection with Watson's Abbreviated New Drug Application (ANDA) for a generic version of LIDODERM.  The lawsuit is in response to a Paragraph IV Certification Notice that advised that Watson had submitted to the FDA an ANDA seeking approval to market a generic version of LIDODERM.  The lawsuit against Watson alleges infringement of Orange Book-listed U.S. Patent No. 5,827,529 that covers the LIDODERM formulation and expires in October 2015.  Endo intends to vigorously defend LIDODERM's intellectual property rights and pursue all available legal a
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014  Tasly Pharmaceuticals, Inc., the ... medicine, announced today the launch of Deepure. ... to address men and women concerned with supporting ... into old age while helping keep their health ... whole-food and herb-based formulas, namely, ProHeart PLUS, ImmunoPower ...
(Date:9/30/2014)... , Sept. 30, 2014 Arbor Pharmaceuticals, ... Summary Global Markets Direct,s, ,Arbor Pharmaceuticals, LLC. ... overview of the Arbor Pharmaceuticals, LLC.,s pharmaceutical research ... information on the current therapeutic developmental pipeline of ... various stages, therapeutics assessment by drug target, mechanism ...
(Date:9/30/2014)... Sept. 30, 2014  Decision Resources Group finds that the ... , China , India ... a strong rate through 2023. Dental implant procedure volumes will grow ... awareness rises. Other key findings from Decision Resources Group,s ... market: , Dental implant penetration: Penetration of dental ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3
... Study Comparing Leading Hepatitis C Therapies Provides ... Insights to Help Guide Clinical Practice, MILAN, Italy, ... first large, randomized, clinical study comparing the,leading therapies for ... Meeting of the European Association for the Study of ...
... of treatment with R7128 1500mg BID with Pegasys(R) plus Copegus(R) -, - Safety and ... ... presentation available on Pharmasset website -, - Conference call scheduled for Friday, April 25, 2008 at ... and 7:00 PM CEST (Milan) -, ...
Cached Medicine Technology:Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 2Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 3Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 4Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 5Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 6Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 7Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 8Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 9Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL) 10Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 2Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 3Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 4Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 5Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C 6
(Date:10/1/2014)... research co-funded by the Engineering and Physical Sciences ... of the UK,s vital industrial control systems which ... electricity grid, and the rail network. , ... from hackers or malware infiltrating the systems behind ... Institute in Trustworthy Industrial Control Systems (RITICS), based ...
(Date:10/1/2014)... 01, 2014 Marriagelifeinsurance.com has released ... insurance for retired couples. , Senior citizens can ... security for their loved ones. A joint policy is ... persons pass away. , Life insurance can be ... insurance can even be purchased online, as the application ...
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... business worldwide. This rapid growth includes increased hiring for ... efforts. The company has experienced average annual growth rates ... this growth to continue in the future as new ... , “We are very pleased that UV ...
(Date:10/1/2014)... 01, 2014 Beverly Hills licensed Clinical ... is celebrating 20 years of private practice in her ... people to achieve greater joy and fulfillment in their ... warning signs and suggestions for anyone who suspects they ... “Believe it or not, it’s not always easy ...
(Date:10/1/2014)... Anti Aging Clinic (AntiAgingClinic.ca), the Greater ... of choice, is announcing a discounted cost on Botox ... , “We’re doing this because we want to give ... skin clinic in Toronto,” says Dr. Brian Sieber, founder ... Anti Aging Clinic, including laser facials, genesis laser facials, ...
Breaking Medicine News(10 mins):Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Anti Aging Clinic, the GTA’s Premier Provider of Anti Aging Treatments, Announces Deal on Units of Botox 2
... June 13 (Pink Sheets: ICTY) As of,June 11, ... that is,going to completely revamp the company and move ... very tight and secure team of corporate,individuals are in ... must be addressed prior to the release of any ...
... HILL, N.C., June 13 Market competition ... interest of the most highly,qualified clinical investigators. ... clinical investigators to their studies win an ... Best Practices, LLC,s white paper "Recruiting and ...
... could detect disease sooner, when it,s more treatable , , FRIDAY, ... development of pancreatic cancer have been identified by U.S. researchers, ... to develop a blood test to detect this type of ... , "Our team identified, for the first time, protein ...
... Paris, France, Friday 13 June 2008: Rheumatoid ... (PsA) patients should undergo compulsory cardiovascular (CV) risk ... adapted to the increased CV risk in inflammatory ... ,Cardiovascular Risk Management in RA, recommended today at ...
... End of Life Urges Congress to Preserve ... Compassionate End-of-Life Care, WASHINGTON, June ... Payment Advisory Commission (MedPAC),reported that the rapid growth of the Medicare ... and more spending per,beneficiary. According to the report, "Evaluating Medicare,s Hospice,Benefit," ...
... 13 June 2008: A new DNA microarray chip can ... arthritis (RA), as presented today at EULAR 2008, the ... Paris, France. The chip (called the ,ARTchip,) has yielded ... in anticipating likely disease progression and prognosis and thereby ...
Cached Medicine News:Health News:EyeCity.com, Inc. Changes Ownership and Moves Into a New Direction 2Health News:Pancreatic Cancer Biomarkers Found 2Health News:CV risk management should be mandatory in RA and other types of inflammatory rheumatic disease 2Health News:CV risk management should be mandatory in RA and other types of inflammatory rheumatic disease 3Health News:More Data Needed Before Changing Medicare Hospice Funding, Report Finds 2Health News:More Data Needed Before Changing Medicare Hospice Funding, Report Finds 3Health News:Novel DNA microarray chip predicts functional impairment and remission in rheumatoid arthritis 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: